Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like the Ibox, Great job here. Go $ATPT
Thank you, Hope we all do well. Go $ATPT
Mine is fine, Go $SVTE
Hope all is well with everyone, I'm tied up in pennies.
Also the cars, Hoping to be back to big boards soon.
Good luck and god bless!
Wow nice $ATPT up just shy of 100% today, from morning low 0.0023 - 0.0045
Yo, Go $ABVG. Still hanging on, Hoping for something soon!
Looks like something is up. Go $ATPT!
Weak, Very nice movement. $ATPT 0.004 0.001 +33.33 20,337,769 0.0039 0.004
$ATPT patience is what this one is about.
$ATPT shares are in strong hands!
Yep, Still up 3000% on my $ATPT free shares!
Volkswagen's recent announcement of a $40 billion spending commitment on electric vehicles is the latest signal of a red-hot bull market.
The rise in global demand for electric vehicles has ushered in the next long-term megatrend that investors need to monitor:
The lithium boom has begun.
With lithium carbonate prices already soaring more rapidly than expected, a fast-moving scenario has been triggered.
One exploration company - thanks to a large, high-grade deposit - stands poised to help investors realize extraordinary potential from the lithium boom.
I've prepared a brief investor's report that reveals the name of this company - as well more details about what you should expect to happen next.
https://microsmallcap.com/bearing-lithium/brz-1/time-invest-lithium-lithium-miner-see-serious-upside-lithium-demand-soars/
I have been playing $PVCT Since 52 week low,
I like this stock alot!
lol
$PVCT, Provectus News
PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS
- Responses mediated by multiple pathways, including IL-17, IL-22 and interferons -
- Down-regulation of more than 500 disease-related genes; wide range of central "psoriasis-related" genes effectively normalized -
Thursday November 30, 2017
KNOXVILLE, TN., /Globe Newswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com), ("Provectus" or the "Company"), a clinical-stage biotechnology company developing a novel therapeutic platform based on halogenated xanthenes for the treatment of multiple diseases, including cancer and inflammatory dermatoses, today announced that results from the Company’s mechanism of action ("MOA") study of PH-10 were presented at the 8th International Congress of Psoriasis: from gene to clinic ("Psoriasis G2C"), held in London, England from November 30th to December 2nd. This MOA work was undertaken by James Krueger, MD, PhD and other members of the Laboratory for Investigative Dermatology at The Rockefeller University. PH-10 is a topical hydrogel formulation that yields selective delivery of rose bengal disodium to epithelial tissues.
The MOA work used tissue biopsy specimens collected from participants in a multicenter study of subjects with mild to moderate psoriasis (NCT02322086). Patients applied a vehicle treatment each day for 28 consecutive days to plaque psoriasis on the central part of their bodies or extremities, and then applied PH-10 each day for 28 consecutive days to these same areas. Biopsies of one target plaque were collected at baseline (at least 7 days prior to first study treatment on Day 1), and then at Days 29 and 64 (with a 7-day interval between the biopsy at Day 29 and the commencement of PH-10 application on Day 36). Study data from each subject served as an internal control (i.e., non-lesional skin and plaque skin assessment at baseline and serial biopsies at the end of the applications of the vehicle and PH-10, respectively) to assess patients' clinical and cellular responses to PH-10.
Topical PH-10 Results from MOA Study Presented at Psoriasis G2C:
The vehicle treatment did not significantly alter the expression of core IL-17- or IL-23-modulated genes, or the overall disease transcriptome.
PH-10 treatment significantly down-regulated IL-17A, IL-22, IL-26, IL-36 and keratin 16 genes.
Pathways significantly improved by PH-10 treatment included published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22 and interferons.
PH-10 treatment also resulted in the downregulation of more than 500 disease-related genes. The expression of a wide-range of central "psoriasis-related" genes including IL-23, IL-17, IL-22, S100A7, IL-19, IL-36 and CXCL1 were effectively normalized to levels consistent with non-lesional skin.
Dominic Rodrigues, Chairman of the Company's Board of Directors, said, "This study has elucidated PH-10's novel mechanism of action for psoriasis and, combined with Provectus' prior clinical work in inflammatory dermatoses, reaffirmed our belief that the Company's therapeutic platform may now encompass psoriasis and also extend to other skin disorders. The immunologic response outcome that four weeks of topical PH-10 achieved in this study occurs with other topical or systemic drugs approved for psoriasis."
Mr. Rodrigues added, "We believe Dr. Krueger's foundational analysis of immune and psoriasis-related gene modulation by PH-10 confirms its clinical relevancy, albeit in a brief, four-week treatment regimen. This prior regimen was studied by Provectus in multiple Phase 1 and 2 clinical studies of psoriasis and atopic dermatitis comprising more than 200 patients; minimal adverse effects were observed and efficacy was evident in all metrics, such as psoriasis severity index, plaque response assessment, pruritus self-assessment, eczema area severity index, and investigator's global assessment."
Mr. Rodrigues concluded, "Provectus is now in the position to establish the full efficacy potential of topical PH-10. We are refining our clinical development program for dermatology to include longer administration of PH-10 that would allow for its direct comparison with both topical and systemic approved drugs."
A copy of the poster presentation is available on Provectus' website at http://www.provectusbio.com/media/docs/publications/PVCT_PG2C2017.pdf
The complete press release is available at http://www.provectusbio.com/news/press-releases/provectus-pr-20171130-1 on the Provectus website.
Hey buddy, Hope all is well.
Me i have been wicked busy lately!
Best thing to do is your DD, On iffy days shut the computer off.
Go $ATPT
Ridiculous for weak people to sell down here. Go $ATPT
$ATPT loading zone, Nice!
Nice, All us Irish are probably related. lol
Really nice pictures, Thanks.
Hope $ATPT Explodes upward this week!
Might be last chance for $ATPT cheapies.
News coming soon!
I added more the other day, Go $ATPT
Happy thanksgiving buddy!
$ATPT DD_dempsey Member Level Thursday, 11/23/17 02:29:12 PM
Re: SharkStocks post# 13787
Post # of 13795
FANTASTIC $ATPT update- confirmed so much
We are CURRENT and the CE is coming off any day straight from the CEO. NO TOXIC DEBTS
AND THE MOST IMPORTANT THING- a tight lipped CEO- who knows all material events must come from an 9K and not to shareholders by email etc.
This was an amazing update and one of the best for thanksgiving. I am aware of the exact same info and the only thing more - which is also in the filing -- IS THE CONFIRMATION THAT THEY ARE WORKING WITH SEVERAL ACQUSITIONS/MERGERs - and I believe we are going to have quite a few very awesome sessions about to occur as this is definitely going otcsee major changes to otc markets by next week IMO.
Again- thank you and happy thanksgiving. It's always awesome to get a third confirmation of your DD. This was great.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136406713
Have a nice thanksgiving everyone!
Nice job!
I can't wait for news on $ATPT, I might add some more tomorrow.
The market sure is scary, Hope all is well with you and yours!
Yep, Rome ($ABVG) wasn't built in a day.
Looks like its coming together, Just not as fast as some would like!
If news drops pre on monday, $ATPT going to get fun in a hurry!
GM Rainer, Hope all is well!
Kinda old news, Effective on October 20, 2017, J. Scott Webber resigned as President and CEO and appointed Mark A. Miller as President. Mr. Miller is also the sole director of the Company.
GM all, Hoping for a great day here!
Buddy, Did you ever get in $ATPT?
Java sent me a pm over there, I'm not going back!
Good day coming for $ATPT today!
Thanks, $VNTH on watch
Great call, Go $ICBU
I agree, I'm being selective. Waiting for the market to take a huge dip.
Then we will make out bigly, On the RIP!
I hate pennies, But got to go with the flow!
$ATPT has been one of the best stocks, i have seen (in forever)!